about
Changing incidence of esophageal cancer among white women: analysis of SEER data (1992-2010).A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung CancerChemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012.The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer.Variation in geographic access to chemotherapy by definitions of providers and service locations: a population-based observational studyGeographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancerGermline mutations predisposing to non-small cell lung cancer.O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.Peer-assisted Learning: Intensity-modulated Radiotherapy Transition in Developing Countries.Cancer care for adolescents and young adults in JordanO2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateAtezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis
P50
Q31021539-7CFC146C-1F31-43A0-BEE0-E676D5AC2466Q33435705-2CDAFF7D-50BF-47F6-968D-BDF3C60C3A29Q34899436-ED2E3AC0-74A7-4DE7-831F-78265F31FEBFQ35542896-9F747D5D-76ED-4D57-9B8E-AE4E204E8386Q36080801-65C8F9E8-F6D6-48E4-9842-58383BFA4263Q36774403-91D02095-CC53-4222-9958-411F345FC1D5Q38392359-72ABE95E-7C3B-448A-88A7-E0B112469B9AQ38709364-523B1041-2DF1-4FDD-A0CC-FBA86B7E2B1AQ50434009-7F8AF3A2-C074-48E3-951D-A4ADCA92612FQ57160037-C5628260-C65B-4C16-AF26-3F46D81A2F6BQ57598558-098A182C-C981-42A3-AE4B-D5A5BC5A3656Q88791416-930B3BC1-7D9B-441B-887B-CCBB1F706AF3Q90041488-2348CF94-1A00-4336-9ED7-024832832759
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Taher Abu Hejleh
@ast
Taher Abu Hejleh
@en
Taher Abu Hejleh
@es
Taher Abu Hejleh
@nl
type
label
Taher Abu Hejleh
@ast
Taher Abu Hejleh
@en
Taher Abu Hejleh
@es
Taher Abu Hejleh
@nl
prefLabel
Taher Abu Hejleh
@ast
Taher Abu Hejleh
@en
Taher Abu Hejleh
@es
Taher Abu Hejleh
@nl
P1153
55192450300
P31
P496
0000-0002-2476-4879